Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort

OBJECTIVES: Immunotherapy plus chemotherapy has recently been applied in the neoadjuvant treatment for locally advanced gastric cancer (LAGC), while its superiority over neoadjuvant chemotherapy (NACT) alone remains to be explored. This study explored the safety and efficacy of NACT plus tislelizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qi, Liu, Weizhen, Zeng, Xiangyu, Zhang, Chenggang, Du, Yuqiang, Zeng, Liwu, Yin, Yuping, Fan, Jun, Yang, Ming, Tao, Kaixiong, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195027/
https://www.ncbi.nlm.nih.gov/pubmed/37215127
http://dx.doi.org/10.3389/fimmu.2023.1122121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195027/
https://www.ncbi.nlm.nih.gov/pubmed/37215127
http://dx.doi.org/10.3389/fimmu.2023.1122121

Ejemplares similares